Statins and Hepatotoxicity
Year: 2007
Type: article
Abstract: Since 1987, statins are among the most widely prescribed medications for primary and secondary prevention of cardiovascular disease around the world. Numerous clinical trials and extensive clinical experience have established that currently available statins have an excellent safety profile. Asymptomatic elevations in liver enzymes are common in patients treated with statins due to a pharmacodynamic effect of lipid lowering, but clinically significant liver injury is extremely rare. The incidence of significant elevation in alanine aminotransferase levels (>3 times upper limit of normal on two or more measurements) is dose-related and generally less than 3%. These asymptomatic aminotransferase elevations may occur in all lipid lowering agents including ezetimide which has no effect on liver metabolism and could be caused by changes in hepatocyte membrane composition.
Source: Annals of Gastroenterology
Author: Spyridon P. Dourakis
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W1870720499